Saturday 27 August 2016
 
»
Tag
 
»
Hikma

Hikma reports 24pc increase in revenue

Hikma Pharmaceuticals, a multinational pharmaceutical company, has reported a revenue of $882 million for the first half of this year, a 24 per cent increase over the same period last year. The group’s revenue includes the c

More…

Hikma reports 24pc increase in revenue

Hikma Pharmaceuticals, a multinational pharmaceutical company, has reported a revenue of $882 million for the first half of this year, a 24 per cent increase over the same period last year. The group’s revenue includes the c

More…

Hikma revenues hit $1.4bn, up 2pc

Hikma Pharmaceuticals, a leading multinational pharmaceutical group, has posted a revenue of $1.44 billion last year, up two per cent, following a strong year in 2014.   The injectables revenue climbed three per

More…

Hikma's H1 revenue hits $709m

Hikma Pharmaceuticals, the leading multinational pharmaceutical group, has reported a revenue of $709 million for the first half of the year, in line with expectations and strategic progress.   The firm has launc

More…

Hikma to acquire Roxane for $2.65bn

Hikma Pharmaceuticals, a leading multinational pharmaceutical group, is set to acquire Roxane Laboratories and Boehringer Ingelheim Roxane, from Boehringer Ingelheim. The acquisition has an aggregate value of gross consideration o

More…

Hikma in bid for Boehringer's generics unit

Jordan's Hikma Pharmaceuticals has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the US-based Boehr

More…

Hikma in bid for Boehringer's generics unit

Jordan's Hikma Pharmaceuticals has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the US-based Boehr

More…

Hikma Pharmaceuticals posts 9pc revenue increase

Hikma Pharmaceuticals, a leading multinational pharmaceutical group with operations across the Middle East and North Africa (Mena), Europe and the United States, has posted a nine per cent increase in revenue, with returns of $1.4 billion last y

More…

Hikma signs license deal with Azanta for Nimoral

Hikma Pharmaceuticals, a leading multinational pharmaceutical group, has signed an exclusive license agreement with specialty pharmaceutical company Azanta for its proprietary cancer product Nimoral (nimorazole).   Nimoral is

More…

Hikma delivers insights on Mena growth markets

Hikma Pharmaceuticals, a fast growing multinational pharmaceutical group, provided insights on the impact of recent societal, political and economic developments on growth markets in the Arab world at the recently concluded World Economic Forum

More…
 1 2 3 4 5 >  Last ›

calendarCalendar of Events

Ads